COMPLETED

Home Transfusion for HEME

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions

Official Title

A Home Transfusion Program for Patients With Advanced Hematologic Malignancies

Quick Facts

Study Start:2024-10-18

Study Completion:2025-05-21

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT05509439

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients with advanced hematologic malignancies: * Diagnosis of a hematologic malignancy * Age ≥ 18 years * Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment) * Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction * Physician-estimated prognosis of six months or less * Has an adult informal caregiver that lives in the same residence * Patient resides within catchment served by Care Dimensions Hospice * Caregivers: * Identified informal caregiver of enrolled patient with hematologic malignancy * Age ≥ 18 years	* Patients * Age \< 18 years * Does not have an identified adult informal caregiver who lives in the same residence * History of previous serious adverse transfusion reaction * Presence of decompensated congestive heart failure * Caregiver * Age \< 18 years * Our study will exclude members of the following special populations: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners

Inclusion Criteria

Exclusion Criteria

* Patients with advanced hematologic malignancies:
* Diagnosis of a hematologic malignancy
* Age ≥ 18 years
* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction
* Physician-estimated prognosis of six months or less
* Has an adult informal caregiver that lives in the same residence
* Patient resides within catchment served by Care Dimensions Hospice
* Caregivers:
* Identified informal caregiver of enrolled patient with hematologic malignancy
* Age ≥ 18 years

* Patients
* Age \< 18 years
* Does not have an identified adult informal caregiver who lives in the same residence
* History of previous serious adverse transfusion reaction
* Presence of decompensated congestive heart failure
* Caregiver
* Age \< 18 years
* Our study will exclude members of the following special populations:
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners

Contacts and Locations

Principal Investigator

Oreofe O Odejide, MD, MPH

PRINCIPAL_INVESTIGATOR

Dana-Farber Cancer Institute

Study Locations (Sites)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

Oreofe O Odejide, MD, MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-18

Study Completion Date2025-05-21

Study Record Updates

Study Start Date2024-10-18

Study Completion Date2025-05-21

Terms related to this study

Keywords Provided by Researchers

Hematologic Malignancy

Additional Relevant MeSH Terms

Hematologic Malignancy